Prediction and Prevention of Type 1 Diabetes
Open Access
- 2 June 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 11, 248
Abstract
Type 1 Diabetes (T1D) is one of the most common chronic autoimmune diseases in children. The disease is characterized by the destruction of beta cells, leading to hyperglycemia, and to a lifelong insulin-dependent state. Although several studies in the last decades have added relevant insights, the complex pathogenesis of the disease is not yet completely understood. Recent studies have been focused on several factors, including family history and genetic predisposition (HLA and non-HLA genes) as well as environmental and metabolic biomarkers, with the aim of predicting the development and progression of T1D. Once a child becomes symptomatic, beta cell mass has already reached a critical threshold (usually a residual of 20–30% of normal amounts), thus representing only the very late phase of the disease. In particular, this final stage follows two preceding asymptomatic stages, which have been precisely identified. In view of the long natural history and complex pathogenesis of the disease, many strategies may be proposed for primary, secondary, and tertiary prevention. Strategies of primary prevention aim to prevent the onset of autoimmunity against beta cells in asymptomatic individuals at high risk for T1D. In addition, the availability of novel humoral and metabolic biomarkers that are able to characterize subjects at high risk of progression, have stimulated several studies on secondary and tertiary prevention, aimed to preserve residual beta cell destruction and/or to prolong the remission phase after the onset of T1D. This review focuses on the major current knowledge on prediction and prevention of T1D in children.Keywords
This publication has 111 references indexed in Scilit:
- Antigen Targets of Type 1 Diabetes AutoimmunityCold Spring Harbor Perspectives in Medicine, 2012
- Antigen-Specific Therapeutic Approaches in Type 1 DiabetesCold Spring Harbor Perspectives in Medicine, 2011
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Enterovirus RNA in Blood Is Linked to the Development of Type 1 DiabetesDiabetes, 2010
- Genetics of Type 1 Diabetes: What's Next?Diabetes, 2010
- Prediction of Type 1 Diabetes in the General PopulationDiabetes Care, 2010
- Prediction and Pathogenesis in Type 1 DiabetesImmunity, 2010
- Etanercept Treatment in Children With New-Onset Type 1 DiabetesDiabetes Care, 2009
- Type I Diabetes MellitusNew England Journal of Medicine, 1986